New data support Tecentriq triplet in lung cancer

27 March 2018
2019_biotech_test_vial_discovery_big

An interim analysis shows that Roche’s (ROG: SIX) Phase III IMpower150 study has met its co-primary endpoint of overall survival (OS).

The trial is exploring a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemo to treat non-squamous non-small cell lung cancer (NSCLC) in the first-line setting.

The triple combo, which is being compared with Avastin and chemo alone, showed a survival benefit across key subgroups, including those with varying levels of PD-L1 expression. No new safety signals were detected.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology